Jivi (damoctocog alfa pegol) / Bayer 
Welcome,         Profile    Billing    Logout  
 10 Diseases   6 Trials   6 Trials   349 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jivi (damoctocog alfa pegol) / Bayer
PREDICT, NCT05036278 / 2021-006191-16: Prophylaxis Regimen for Hemophilia A Patients

Completed
4
21
US
Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG)., Jivi, BAY94-9027
Bayer, Bayer HealthCare Pharmaceuticals Inc.
Hemophilia A, Prophylaxis of Bleeding
09/24
10/24
2021-006191-16: A study to learn how well a new risk score approach works for identifying the best individualized treatment regimen for prevention in hemophilia A patients who switch from standard half-life products to damoctocog alfa pegol (Jivi)

Not yet recruiting
4
21
US
Jivi, BAY94-9027, BAY 94-9027, Powder and solution for solution for injection, Jivi
Bayer HealthCare Pharmaceuticals Inc., Bayer HealthCare Pharmaceuticals Inc.
Hemophilia AProphylaxis of bleeding, Prevention of bleeding in people with hemophilia A, a genetic bleeding disorder that is caused by the lack or non-function of a protein in the blood called “clotting factor 8” (FVIII)., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-004858-30: A Phase 3 safety study of BAY 94-9027 in children 7 to <12 years of age with severe hemophilia A

Not yet recruiting
3
40
Europe
Jivi (500 IU), Jivi (1000 IU), BAY 94-9027, Powder and solvent for solution for injection, Jivi
Bayer Consumer Care AG, Bayer AG
Severe hemophilia A (<1% FVIII:C), Hemophilia A is an X-linked congenital bleeding disorder causing frequent bleedings and recurrent spontaneous bleeds into the soft tissue and joints, leading to joint damage and severe disability., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Alfa-PROTECT, NCT05147662 / 2021-004858-30: A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Active, not recruiting
3
33
Europe, Canada, US, RoW
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer, Bayer AG
Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
01/24
05/25
REAL, NCT05395858: A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers

Terminated
N/A
14
US
No intervention
Bayer
Hemophilia A
11/23
11/23
NCT06222697: A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Recruiting
N/A
600
RoW
Damoctocog-alfa-pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A, Prophylaxis of Bleeding, Treatment of Bleeding
03/26
06/26
JOIHA, NCT05643560: An Observational Study Called to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.

Recruiting
N/A
33
Europe
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A, Prophylaxis of Bleeding
03/27
06/27
HEM-POWR, NCT03932201: Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Active, not recruiting
N/A
371
Europe, Canada, Japan, US, RoW
Damoctocog alfa pegol (Jivi, Bay94-9027)
Bayer
Hemophilia A
12/26
03/27
LIFE-ACTIVE, NCT04091386: Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

Active, not recruiting
N/A
10
Europe, Canada, US, RoW
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A
05/24
06/27
HA-SAFE, NCT04461639: Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

Active, not recruiting
N/A
62
Europe
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A
06/28
06/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jivi (damoctocog alfa pegol) / Bayer
PREDICT, NCT05036278 / 2021-006191-16: Prophylaxis Regimen for Hemophilia A Patients

Completed
4
21
US
Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG)., Jivi, BAY94-9027
Bayer, Bayer HealthCare Pharmaceuticals Inc.
Hemophilia A, Prophylaxis of Bleeding
09/24
10/24
2021-006191-16: A study to learn how well a new risk score approach works for identifying the best individualized treatment regimen for prevention in hemophilia A patients who switch from standard half-life products to damoctocog alfa pegol (Jivi)

Not yet recruiting
4
21
US
Jivi, BAY94-9027, BAY 94-9027, Powder and solution for solution for injection, Jivi
Bayer HealthCare Pharmaceuticals Inc., Bayer HealthCare Pharmaceuticals Inc.
Hemophilia AProphylaxis of bleeding, Prevention of bleeding in people with hemophilia A, a genetic bleeding disorder that is caused by the lack or non-function of a protein in the blood called “clotting factor 8” (FVIII)., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-004858-30: A Phase 3 safety study of BAY 94-9027 in children 7 to <12 years of age with severe hemophilia A

Not yet recruiting
3
40
Europe
Jivi (500 IU), Jivi (1000 IU), BAY 94-9027, Powder and solvent for solution for injection, Jivi
Bayer Consumer Care AG, Bayer AG
Severe hemophilia A (<1% FVIII:C), Hemophilia A is an X-linked congenital bleeding disorder causing frequent bleedings and recurrent spontaneous bleeds into the soft tissue and joints, leading to joint damage and severe disability., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Alfa-PROTECT, NCT05147662 / 2021-004858-30: A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Active, not recruiting
3
33
Europe, Canada, US, RoW
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer, Bayer AG
Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
01/24
05/25
REAL, NCT05395858: A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers

Terminated
N/A
14
US
No intervention
Bayer
Hemophilia A
11/23
11/23
NCT06222697: A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Recruiting
N/A
600
RoW
Damoctocog-alfa-pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A, Prophylaxis of Bleeding, Treatment of Bleeding
03/26
06/26
JOIHA, NCT05643560: An Observational Study Called to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.

Recruiting
N/A
33
Europe
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A, Prophylaxis of Bleeding
03/27
06/27
HEM-POWR, NCT03932201: Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Active, not recruiting
N/A
371
Europe, Canada, Japan, US, RoW
Damoctocog alfa pegol (Jivi, Bay94-9027)
Bayer
Hemophilia A
12/26
03/27
LIFE-ACTIVE, NCT04091386: Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

Active, not recruiting
N/A
10
Europe, Canada, US, RoW
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A
05/24
06/27
HA-SAFE, NCT04461639: Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

Active, not recruiting
N/A
62
Europe
Damoctocog alfa pegol (Jivi, BAY94-9027)
Bayer
Hemophilia A
06/28
06/28

Download Options